The BOOSTER study offers the first prospective evidence that adding local ablation to ongoing anti–PD-1/L1 therapy can improve disease control in advanced NSCLC patients with oligo-residual disease. It also helps define a clearer treatment approach for patients who have limited residual lesions after an initial immunotherapy response—an area previously lacking clinical guidance. Read the article
Key findings:
· Median progression-free survival more than doubled in the ablation + immunotherapy arm (26.7 months vs. 11.7 months).
· Cryoablation also led to an increase in systemic IFN-α, suggesting a distinct immunologic effect compared with thermal ablation.
· The combination approach demonstrated an overall favorable safety profile.
Clinical relevance:
Hygea’s cryoablation system may provide more than local tumor control—its immunomodulatory characteristics could offer meaningful support to ongoing immunotherapy, especially for patients with limited residual disease.
This study reinforces the emerging role of ablation as a valuable component within combined minimally invasive and immunotherapeutic strategies.
EN 
